Vaxart Inc Asset Resilience Ratio
Vaxart Inc asset resilience ratio. Vaxart Inc (VXRT) has an Asset Resilience Ratio of 5.71% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Vaxart Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Vaxart Inc (2004–2025)
Asset resilience ratio of Vaxart Inc from 2004 to 2025. This chart shows how Vaxart Inc's Asset Resilience Ratio has changed over time. Read Vaxart Inc (VXRT) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Vaxart Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see VXRT current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.28 Million | 5.71% |
| Total Liquid Assets | $10.28 Million | 5.71% |
Asset Resilience Insights
- Limited Liquidity: Vaxart Inc maintains only 5.71% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Vaxart Inc Industry Peers by Asset Resilience Ratio
Compare Vaxart Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Vaxart Inc Asset Resilience Ratio by Year (2004–2025)
Vaxart Inc asset resilience ratio by year from 2004 to 2025. The table below shows the annual Asset Resilience Ratio data for Vaxart Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.37% | $9.99 Million | $186.08 Million | -10.55pp |
| 2024-12-31 | 15.92% | $26.49 Million | $166.39 Million | +10.52pp |
| 2023-12-31 | 5.40% | $4.96 Million | $91.83 Million | -26.91pp |
| 2022-12-31 | 32.31% | $49.70 Million | $153.85 Million | +22.02pp |
| 2021-12-31 | 10.28% | $22.74 Million | $221.17 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $152.58 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $35.23 Million | -- |
| 2017-12-31 | 52.12% | $20.90 Million | $40.10 Million | +25.57pp |
| 2016-12-31 | 26.55% | $19.30 Million | $72.70 Million | +10.30pp |
| 2015-12-31 | 16.25% | $12.90 Million | $79.40 Million | +4.93pp |
| 2014-12-31 | 11.32% | $12.90 Million | $114.00 Million | +9.19pp |
| 2011-12-31 | 2.12% | $2.08 Million | $97.97 Million | -45.83pp |
| 2010-12-31 | 47.95% | $54.60 Million | $113.87 Million | +2.65pp |
| 2009-12-31 | 45.30% | $59.49 Million | $131.32 Million | +28.73pp |
| 2008-12-31 | 16.57% | $23.90 Million | $144.22 Million | +15.90pp |
| 2007-12-31 | 0.67% | $1.60 Million | $238.57 Million | -11.55pp |
| 2006-12-31 | 12.22% | $32.50 Million | $265.88 Million | +10.65pp |
| 2005-12-31 | 1.57% | $5.17 Million | $329.34 Million | -0.70pp |
| 2004-12-31 | 2.27% | $8.35 Million | $368.17 Million | -- |
About Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phas… Read more